Acute myeloid leukemia trials in Russia

In Russia 11 Also abroad 761

11 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients
Where
Krasnogorsk, Moscow, Saint Petersburg, Velikiy Novgorod
Age
18 years and over
People
66 worldwide
Run by
Lomond Therapeutics Holdings, Inc.
See details and how to joinNCT07303660
Phase 2/3Taking people
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Where
Moscow
Age
1 year to 25 years
People
64
Run by
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
See details and how to joinNCT07366801
Phase 2Taking people
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
Where
Moscow
Age
1 month to 25 years
People
15
Run by
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
See details and how to joinNCT07256210
Phase 3Taking people
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Where
Moscow, Saint Petersburg
Age
18 years and over
People
486 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06389292 · EU 2024-516436-10-00
Phase 3Taking people
The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia
Where
Moscow
Age
1 day to 18 years
People
100
Run by
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
See details and how to joinNCT07232134
Phase 2Taking people
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
Where
Saint Petersburg
Age
18 years to 70 years
People
60
Run by
St. Petersburg State Pavlov Medical University
See details and how to joinNCT07238712
Phase 2/3Taking people
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Where
Moscow
Age
1 day to 21 years
People
50
Run by
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
See details and how to joinNCT06756152
Phase 2Taking people
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
Where
Saint Petersburg
Age
18 years to 75 years
People
88
Run by
St. Petersburg State Pavlov Medical University
See details and how to joinNCT06532084
Phase 2Taking people
Vitamin A and D Supplementation in Allogeneic HCT
Where
Saint Petersburg
Age
18 years and over
People
220
Run by
St. Petersburg State Pavlov Medical University
See details and how to joinNCT06508099
Phase 2Taking people
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
Where
Saint Petersburg
Age
18 years to 75 years
People
220
Run by
St. Petersburg State Pavlov Medical University
See details and how to joinNCT06477549
Phase 3Taking people
IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML
Where
Moscow
Age
18 years and over
People
198
Run by
National Research Center for Hematology, Russia
See details and how to joinNCT06418776